Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemothe
Autor:
Daniel Weiss, Liangang Liu, Simon Zhou, Josephine Reyes, Nianhang Chen, Gondi Kumar, Lilia Weiss, Xiaomin Wang, Claudia Kasserra, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Lenalidomide, a weak substrate of P-glycoprotein (P-gp) in vitro, is an oral anticancer drug eliminated predominantly via renal excretion as unchanged compound. The role of P-gp in lenalidomide disposition and the associated clinical relevanc
Autor:
Yasuo Ohkura, Tomokazu Kishiki, Tadahiko Masaki, Takashi Watanabe, Jyunji Furuse, Kouki Ohtsuka, Hiroaki Ohnishi, Masanori Sugiyama
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are acti